David Radspinner

David Radspinner has a diverse work experience in the biotechnology and healthcare industry. David is currently serving as the Chief Executive Officer at VintaBio since March 2023. Prior to that, they worked as a Consultant at D Radspinner LLC from August 2022 to April 2023.

Before their role at D Radspinner LLC, David served as the President of Biotherapeutics at ILC Dover from December 2020 to August 2022. David also worked as the VP/GM Global Commercial Transition at Cytiva (formerly GE Life Sciences) from April 2020 to December 2020.

Furthermore, David has held various leadership positions at GE Healthcare, including the role of VP/GM Americas GE Biopharma from September 2016 to April 2020. In this role, they were responsible for managing the GEHC BioPark, a biopharmaceutical manufacturing campus in Cork, Ireland. David also served as the General Manager of HyClone Cell Culture from March 2014 to September 2016.

Earlier in their career, David worked at Thermo Fisher Scientific where they held positions such as Global Head of Sales - Bioproduction from January 2011 to March 2014, Global Head of Marketing and Product Management from August 2007 to January 2011, and PAT Director from April 2005 to September 2007.

At the start of their career, David worked at Aventis Pharmaceuticals where they held the role of Head of Process Analytical Technology - Drug Product and Manager of Inhaler Product and Process Development. In these roles, they led teams in developing real-time analytics and advanced predictive modeling for drug products and inhalers. David also worked with the US FDA on regulatory and inspection concepts within the PAT framework.

David Radspinner completed their Bachelor of Arts degree in Chemistry from Wabash College, where they studied from 1983 to 1987. David then pursued a higher level of education and obtained a PhD in Chemistry from the University of Arizona, where they were enrolled from 1987 to 1992.